» Articles » PMID: 36581731

Neuroprotective Effects of Conditioned Medium of Mesenchymal Stem Cells (MSC-CM) As a Therapy for Ischemic Stroke Recovery: A Systematic Review

Overview
Journal Neurochem Res
Specialties Chemistry
Neurology
Date 2022 Dec 29
PMID 36581731
Authors
Affiliations
Soon will be listed here.
Abstract

It has been reported that the therapeutic potential of stem cells is mainly mediated by their paracrine factors. In order to identify the effects of conditioned medium of mesenchymal stem cells (MSC-CM) against stroke, a systematic review was conducted. We searched PubMed, Scopus, and ISI Web of Science databases for all available articles relevant to the effects of MSC-CM against the middle cerebral artery occlusion (MCAO) model of ischemic stroke until August 2022. The quality of the included studies was evaluated using The STAIR scale. During the systematic search, a total of 356 published articles were found. A total of 15 datasets were included following screening for eligibility. The type of cerebral ischemia was the MCAO model and CM was obtained from MSCs. The results showed that the therapeutic time window can be considered a crucial factor when researchers use MSC-CM for stroke therapy. In addition, MSC-CM therapy contributes to functional recovery and reduces infarct volume after stroke by targeting different cellular signaling pathways. Our findings showed that MSC-CM therapy has the ability to improve functional recovery and attenuate brain infarct volume after ischemic stroke in preclinical studies. We hope our study accelerates needed progress towards clinical trials.

Citing Articles

Mesenchymal Stem Cell Priming: Potential Benefits of Administration of Molecular Hydrogen.

Artamonov M, LeBaron T, Pyatakovich F, Minenko I Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675429 PMC: 11054387. DOI: 10.3390/ph17040469.


Effects of mesenchymal stem cell on dopaminergic neurons, motor and memory functions in animal models of Parkinson's disease: a systematic review and meta-analysis.

Park J, Rahmati M, Lee S, Shin J, Kim Y Neural Regen Res. 2023; 19(7):1584-1592.

PMID: 38051903 PMC: 10883506. DOI: 10.4103/1673-5374.387976.


A mutant methionyl-tRNA synthetase-based toolkit to assess induced-mesenchymal stromal cell secretome in mixed-culture disease models.

Burgess J, Amerna D, Norton E, Parsons T, Perkerson 3rd R, Faroqi A Stem Cell Res Ther. 2023; 14(1):289.

PMID: 37798772 PMC: 10557244. DOI: 10.1186/s13287-023-03515-0.


A Mutant Methionyl-tRNA Synthetase-Based toolkit to assess induced-Mesenchymal Stromal Cell secretome in mixed-culture disease models.

Burgess J, Amerna D, Norton E, Parsons T, Perkerson 3rd R, Faroqi A Res Sq. 2023; .

PMID: 37205579 PMC: 10187403. DOI: 10.21203/rs.3.rs-2838195/v1.

References
1.
Chamorro A, Dirnagl U, Urra X, Planas A . Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016; 15(8):869-881. DOI: 10.1016/S1474-4422(16)00114-9. View

2.
Phipps M, Cronin C . Management of acute ischemic stroke. BMJ. 2020; 368:l6983. DOI: 10.1136/bmj.l6983. View

3.
Madani Neishaboori A, Nasseri Maleki S, Pirouz M, Golmohammadi S, Nazarinia D, Aboutaleb N . Donepezil attenuates injury following ischaemic stroke by stimulation of neurogenesis, angiogenesis, and inhibition of inflammation and apoptosis. Inflammopharmacology. 2020; 29(1):153-166. DOI: 10.1007/s10787-020-00769-5. View

4.
Ng Y, Stein J, Ning M, Black-Schaffer R . Comparison of clinical characteristics and functional outcomes of ischemic stroke in different vascular territories. Stroke. 2007; 38(8):2309-14. DOI: 10.1161/STROKEAHA.106.475483. View

5.
Kimura K, Minematsu K, Yamaguchi T . Characteristics of in-hospital onset ischemic stroke. Eur Neurol. 2006; 55(3):155-9. DOI: 10.1159/000093574. View